Key facts
- This page summarizes Richard A. Gonzalez's Form 4 filing for AbbVie Inc. (ABBV).
- 5 reported transactions and 1 derivative row are listed below.
- Accepted by SEC: 18 Feb 2025, 17:00.
Richard A. Gonzalez - 13 Feb 2025 Form 4 Insider Report for AbbVie Inc. (ABBV)
- Reporting relationship
- Director
- Issuer ticker
- ABBV
- Reported as of
- 13 Feb 2025
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 18 Feb 2025, 17:00:09 UTC
- Prior SEC filing
- 02 Oct 2024
- Next SEC filing
- 04 Mar 2025
- Source filing
- View source filing
- Reporting owner signature
- /s/ T.O. Odutayo, Attorney-in-Fact for Richard A. Gonzalez
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Richard A. Gonzalez filed Form 4 for AbbVie Inc. (ABBV) on 18 Feb 2025.
Change
- Previous filing in this sequence was filed on 02 Oct 2024.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
ABBV
transaction
Common Stock, $0.01 par value
Award
- Transaction value
- $0
- Shares
- +80,945
- Change %
- +21%
- Price
- $0.000000
- Shares after
- 469,874
- Date
- 13 Feb 2025
- Ownership
- Direct
- Footnotes
- F1
ABBV
transaction
Common Stock, $0.01 par value
Award
- Transaction value
- $0
- Shares
- +33,208
- Change %
- +7.1%
- Price
- $0.000000
- Shares after
- 503,082
- Date
- 13 Feb 2025
- Ownership
- Direct
- Footnotes
- F2
ABBV
transaction
Common Stock, $0.01 par value
Award
- Transaction value
- $0
- Shares
- +30,298
- Change %
- +6%
- Price
- $0.000000
- Shares after
- 533,380
- Date
- 13 Feb 2025
- Ownership
- Direct
- Footnotes
- F3
ABBV
transaction
Common Stock, $0.01 par value
Award
- Transaction value
- $0
- Shares
- +27,386
- Change %
- +5.1%
- Price
- $0.000000
- Shares after
- 560,766
- Date
- 13 Feb 2025
- Ownership
- Direct
- Footnotes
- F4
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
ABBV
transaction
Derivative
Option (Right to Buy)
Award
- Transaction value
- $0
- Shares
- +65,104
- Change %
- Price
- $0.000000
- Shares after
- 65,104
- Date
- 13 Feb 2025
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 65,104
- Exercise price
- $192.86
- Footnotes
- F5
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 5 footnotes
Footnote F1
Represents shares of AbbVie common stock issued under a performance share award granted to the reporting person on February 17, 2022. The award is subject to performance-vesting restrictions based on earnings per share and relative total shareholder return. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2025.
Footnote F2
Represents shares of AbbVie common stock issued under a performance-vesting restricted stock unit award granted to the reporting person on February 17, 2022. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2025.
Footnote F3
Represents shares of AbbVie common stock issued under a performance-vesting restricted stock unit award granted to the reporting person on February 16, 2023. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2025.
Footnote F4
Represents shares of AbbVie common stock issued under a performance-vesting restricted stock unit award granted to the reporting person on February 15, 2024. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2025.
Footnote F5
Employee stock option granted pursuant to the AbbVie Amended and Restated 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 21,702 on February 13, 2026, 21,701 on February 13, 2027, and 21,701 on February 13, 2028.
SEC remarks
Due to an administrative error the exercise price for options awarded February 15, 2024 was previously reported as $0 in Table II Column 2, instead of the correct value of $175.28